Work

Beyond the surgeon's eye: towards a molecular definition of complete cytoreduction in advanced ovarian cancer

Year: 2026

Type: article

Abstract: The volume of residual disease after cytoreductive surgery is the main prognostic factor that the surgical team can influence in advanced ovarian cancer. In the combined analysis of three randomized trials of the Arbeitsgemeinschaft Gynaekologische Onkologie – Ovarian Cancer Study Group (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO), median overall survival reached 99.1 months in patients without visible residual disease, compared with 36.2 months with residual disease of 1–10 mm and 29.6 months with residual disease larger than 10 mm [1].

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2026.11.002

Author: Antoni Llueca

Institution: Universitat Jaume I

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,380